{
  "cik": 1875558,
  "cik_padded": "0001875558",
  "entityName": "Nuvectis Pharma, Inc.",
  "fiscal_years": [
    {
      "accn": "0001104659-26-013044",
      "filed": "2026-02-11",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 31634000.0,
        "eps_diluted": -1.32,
        "net_income": -26442000.0,
        "operating_cash_flow": -16009000.0,
        "operating_income": -27574000.0,
        "stockholders_equity": 18413000.0,
        "total_assets": 31709000.0,
        "total_liabilities": 13296000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.7220985173518709,
        "roa_avg2y": -1.0510374433579777,
        "roa_period_end": -0.8338957393799867,
        "roe_avg2y": -1.8802531465547891,
        "roe_period_end": -1.4360506164123175
      }
    },
    {
      "accn": "0001104659-26-013044",
      "filed": "2026-02-11",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 18533000.0,
        "eps_diluted": -1.11,
        "net_income": -19000000.0,
        "operating_cash_flow": -12247000.0,
        "operating_income": -19847000.0,
        "stockholders_equity": 9713000.0,
        "total_assets": 18607000.0,
        "total_liabilities": 8894000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.9156800164727684,
        "roa_avg2y": -1.0055038103302285,
        "roa_period_end": -1.0211210834632127,
        "roe_avg2y": -1.7340512914118829,
        "roe_period_end": -1.956141253989499
      }
    },
    {
      "accn": "0001558370-25-001496",
      "filed": "2026-02-11",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 19126000.0,
        "eps_diluted": -1.43,
        "net_income": -22260000.0,
        "operating_cash_flow": -15954000.0,
        "operating_income": -22897000.0,
        "stockholders_equity": 12201000.0,
        "total_assets": 19185000.0,
        "total_liabilities": 6984000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.5724120973690681,
        "roa_avg2y": -1.124526395554433,
        "roa_period_end": -1.1602814698983581,
        "roe_avg2y": -1.6850870552611659,
        "roe_period_end": -1.8244406196213425
      }
    },
    {
      "accn": "0001558370-25-001496",
      "filed": "2025-02-25",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 19993000.0,
        "eps_diluted": -1.51,
        "net_income": -19085000.0,
        "operating_cash_flow": -13559000.0,
        "operating_income": -19234000.0,
        "stockholders_equity": 14219000.0,
        "total_assets": 20405000.0,
        "total_liabilities": 6186000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.43505169139883254,
        "roa_avg2y": -1.4104648584731359,
        "roa_period_end": -0.9353099730458222,
        "roe_avg2y": -11.887262535035815,
        "roe_period_end": -1.3422181588016036
      }
    },
    {
      "accn": "0001558370-24-002497",
      "filed": "2024-03-05",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 5742000.0,
        "eps_diluted": -3.02,
        "net_income": -12890000.0,
        "operating_cash_flow": -9504000.0,
        "operating_income": -12894000.0,
        "stockholders_equity": -11008000.0,
        "total_assets": 6657000.0,
        "total_liabilities": 2419000.0
      },
      "period_end": "2021-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -1.9363076460868256,
        "roe_avg2y": 2.3398075875839535
      }
    },
    {
      "accn": "0001558370-23-003181",
      "filed": "2023-03-08",
      "fiscal_year": 2020,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -10000.0
      },
      "period_end": "2020-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001104659-26-013044",
    "filed": "2026-02-11",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001875558.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001875558.json"
  },
  "ticker": "NVCT"
}